Sbihi Zineb, Tanita Kay, Bachelet Camille, Bole Christine, Jabot-Hanin Fabienne, Tores Frederic, Le Loch Marc, Khodr Radi, Hoshino Akihiro, Lenoir Christelle, Oleastro Matias, Villa Mariana, Spossito Lucia, Prieto Emma, Danielian Silvia, Brunet Erika, Picard Capucine, Taga Takashi, Abdrabou Shimaa Said Mohamed Ali, Isoda Takeshi, Yamada Masafumi, Palma Alejandro, Kanegane Hirokazu, Latour Sylvain
Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, INSERM UMR 1163, Imagine Institute, Paris, France.
Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
J Clin Immunol. 2022 Apr;42(3):559-571. doi: 10.1007/s10875-021-01188-z. Epub 2022 Jan 9.
X-linked inhibitor of apoptosis protein (XIAP) deficiency, also known as the X-linked lymphoproliferative syndrome of type 2 (XLP-2), is a rare immunodeficiency characterized by recurrent hemophagocytic lymphohistiocytosis, splenomegaly, and inflammatory bowel disease. Variants in XIAP including missense, non-sense, frameshift, and deletions of coding exons have been reported to cause XIAP deficiency. We studied three young boys with immunodeficiency displaying XLP-2-like clinical features. No genetic variation in the coding exons of XIAP was identified by whole-exome sequencing (WES), although the patients exhibited a complete loss of XIAP expression.
Targeted next-generation sequencing (NGS) of the entire locus of XIAP was performed on DNA samples from the three patients. Molecular investigations were assessed by gene reporter expression assays in HEK cells and CRISPR-Cas9 genome editing in primary T cells.
NGS of XIAP identified three distinct non-coding deletions in the patients that were predicted to be driven by repetitive DNA sequences. These deletions share a common region of 839 bp that encompassed the first non-coding exon of XIAP and contained regulatory elements and marks specific of an active promoter. Moreover, we showed that among the 839 bp, the exon was transcriptionally active. Finally, deletion of the exon by CRISPR-Cas9 in primary cells reduced XIAP protein expression.
These results identify a key promoter sequence contained in the first non-coding exon of XIAP. Importantly, this study highlights that sequencing of the non-coding exons that are not currently captured by WES should be considered in the genetic diagnosis when no variation is found in coding exons.
X连锁凋亡抑制蛋白(XIAP)缺陷,也称为2型X连锁淋巴细胞增殖综合征(XLP - 2),是一种罕见的免疫缺陷病,其特征为反复发生噬血细胞性淋巴组织细胞增生症、脾肿大和炎症性肠病。据报道,XIAP的变异,包括错义、无义、移码和编码外显子缺失,可导致XIAP缺陷。我们研究了三名具有免疫缺陷且表现出类似XLP - 2临床特征的小男孩。尽管患者XIAP表达完全缺失,但通过全外显子测序(WES)未在XIAP编码外显子中鉴定到基因变异。
对三名患者的DNA样本进行XIAP整个基因座的靶向二代测序(NGS)。通过HEK细胞中的基因报告基因表达分析和原代T细胞中的CRISPR - Cas9基因组编辑来评估分子研究。
XIAP的NGS在患者中鉴定出三个不同的非编码缺失,预计由重复DNA序列驱动。这些缺失共享一个839 bp的共同区域,该区域包含XIAP的第一个非编码外显子,并包含调控元件和活性启动子特有的标记。此外,我们表明在这839 bp中,该外显子具有转录活性。最后,通过原代细胞中的CRISPR - Cas9缺失该外显子可降低XIAP蛋白表达。
这些结果鉴定出XIAP第一个非编码外显子中包含的关键启动子序列。重要的是,本研究强调当在编码外显子中未发现变异时,在基因诊断中应考虑对目前WES未捕获的非编码外显子进行测序。